Philadelphia Chromosome
Mostrando 1-12 de 90 artigos, teses e dissertações.
-
1. Prevalence of atypical BCR-ABL1 transcript types in adult Philadelphia chromosome-positive acute lymphoblastic leukemia: implications for measurable residual disease
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
2. SÍNTESES E PROPRIEDADES DE FÁRMACOS INIBIDORES DA TIROSINA QUINASE BCR-ABL, UTILIZADOS NO TRATAMENTO DA LEUCEMIA MIELOIDE CRÔNICA
The chronic myeloid leukemia (CML) is characterized by presence of the Philadelphia chromosome (Ph), originated from the translocation between chromosomes 9 and 22. This chromosome generates an abnormal protein tyrosine kinase which is responsible for tumor cell proliferation. The emergence of tyrosine kinase inhibitors (TKIs) has transformed the treatment o
Quím. Nova. Publicado em: 2017-08
-
3. Isolated skin relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplant
Rev. Bras. Hematol. Hemoter.. Publicado em: 2017-03
-
4. l-Amino acid oxidase isolated from Calloselasma rhodostoma snake venom induces cytotoxicity and apoptosis in JAK2V617F-positive cell lines
ABSTRACT BACKGROUND: Myeloproliferative neoplasms are Philadelphia chromosome-negative diseases characterized by hyperproliferation of mature myeloid cells, associated or not with the Janus kinase 2 tyrosine kinase mutation, JAK2V617F. As there is no curative therapy, researchers have been investigating new drugs to treat myeloproliferative neoplasms, incl
Rev. Bras. Hematol. Hemoter.. Publicado em: 2016-06
-
5. Diversity of breakpoints of variant Philadelphia chromosomes in chronic myeloid leukemia in Brazilian patients
Background: Chronic myeloid leukemia is a myeloproliferative disorder characterized by the Philadelphia chromosome or t(9;22)(q34.1;q11.2), resulting in the break-point cluster regionAbelson tyrosine kinase fusion gene, which encodes a constitutively active tyrosine kinase protein. The Philadelphia chromosome is detected by karyotyping in around 90% of chro
Rev. Bras. Hematol. Hemoter.. Publicado em: 2015-02
-
6. Philadelphia-negative chronic myeloproliferative neoplasms
Chronic myeloproliferative diseases without the Philadelphia chromosome marker (Ph-), although first described 60 years ago, only became the subject of interest after the turn of the millennium. In 2001, the World Health Organization (WHO) defined the classification of this group of diseases and in 2008 they were renamed myeloproliferative neoplasms based on
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2012
-
7. Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome
OBJECTIVE: This study aimed to verify the association between human leukocyte antigens and the bcr-abl fusion protein resulting from t(9;22)(q34;q11) in chronic leukemia myeloid and acute lymphoblastic leukemia patients. METHODS: Forty-seven bcr-abl positive individuals were evaluated. Typing was performed bymicrolymphocytotoxicity and molecular biological
Rev. Bras. Hematol. Hemoter.. Publicado em: 2012
-
8. The role of natural killer cells in chronic myeloid leukemia
Chronic myeloid leukemia is a neoplasia resulting from a translocation between chromosomes 9 and 22 producing the BCR-ABL hybrid known as the Philadelphia chromosome (Ph). In chronic myeloid leukemia a proliferation of malignant myeloid cells occurs in the bone marrow due to excessive tyrosine kinase activity. In order to maintain homeostasis, natural killer
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2011-06
-
9. Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
Chronic myeloid leukemia (CML) is rare in the pediatric population, accounting for 2-3% of childhood leukemia cases, with an annual incidence of one case per million children. The low toxicity profile of imatinib mesylate has led to its approval as a front-line therapy in children for whom interferon treatment has failed or who have relapsed after allogeneic
Brazilian Journal of Medical and Biological Research. Publicado em: 2010-06
-
10. Molecular monitoring of BCR-ABL transcripts in patients with chronic myeloid leukemia treated with imatinib using real-time PCR / Monitoramento molecular dos transcritos BCR/ABL de pacientes com leucemia mieloide cronica em uso de imatinibe atraves da tecnica de PCR quantitativo em tempo rela (real-time)
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the presence of Philadelphia chromosome (Ph), the result of bcr and abl gene fusion, which product is a protein with kinase activity, inhibited by imatinib. Imatinib is currently the first-line treatment of CML and molecular monitoring of BCRABL transcripts is essential in monit
Publicado em: 2009
-
11. Expression of active BCR related (ABR) gene in chronic myeloid leukemia (CML) real-time RT-PCR (qPCR) / Estudo da expressão do Gene ABR em leucemia mieloide cronica (LMC) utilizando real-time RT-PCR (qPCR)
Chronic myeloid leukemia (CML) is a clonal proliferative disorder of the hematopoietic stem cell cytogenetically characterized by the Philadelphia (Ph) chromosome, a result of chromosomal translocation t(9;22)(q34;q11). At molecular level, the Ph chromosome results in a fusion gene, the chimerical BCR-ABL which has constitutive tyrosine kinase activity and i
Publicado em: 2006
-
12. Hematologic and cytogenetic response in chronic myeloid leukemia patients treated with inhibitor of tyrosine kinase (imatinib) / "Avaliação da resposta clínica e citogenética em portadores de leucemia mielóide crônica, tratados com inibidor da tirosina quinase (imatinib)"
O STI (imatinib, Glivec) é um inibidor da tirosina quinase BCR-ABL, responsável pela patogênese da leucemia mielóide crônica (LMC). Um total de 110 pacientes com LMC na fase crônica (FC) que falharam ou foram intolerantes ao tratamento com interferon, fase acelerada (FA) e crise blástica (CB) foram tratados com imatinibe entre dezembro de 2000 e setem
Publicado em: 2004